Hospital
West Florida - PPH, LLC
West Florida - PPH, LLC was paid $992K by Medicaid between Jan 2018 and Oct 2024, across 55 billing codes. Its largest line is 99283, emergency room visit (moderate) — 30% of everything it billed.
33Billing provider infoWEST FLORIDA - PPH, LLC
SOUTH PASADENA, FL 33707
SOUTH PASADENA, FL 33707
33aNPI1437591708assigned 07/26/2013
33bProvider typeGeneral Acute Care Hospital
28Total paid$992K
24GClaims53,922
24DCodes billed55
24AFirst – last monthJan 2018 – Oct 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#129 of 163
Median peer was paid$4.77M
This provider vs. median0.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 4,532 | $111K | |
| 2019 | 13,303 | $123K | |
| 2020 | 10,039 | $95K | |
| 2021 | 13,832 | $255K | |
| 2022 | 8,800 | $244K | |
| 2023 | 3,018 | $135K | |
| 2024incomplete | 398 | $29K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 30% | 4,607 | 3,784 | $296K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 21% | 4,522 | 3,560 | $206K |
| 80053 | Comprehensive metabolic panel | 11% | 4,894 | 3,586 | $107K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 8.6% | 3,849 | 1,168 | $85K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.0% | 855 | 629 | $70K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.5% | 971 | 687 | $45K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.9% | 162 | 131 | $19K |
| 85027 | 1.4% | 5,307 | 3,798 | $14K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.4% | 2,318 | 1,753 | $13K |
| 71045 | Radiologic examination, chest; single view | 1.3% | 2,110 | 1,596 | $13K |
| 83735 | 1.2% | 1,748 | 1,274 | $12K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.1% | 299 | 251 | $11K |
43 more codes
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,151 | $9K |
| 81001 | <1% | 1,780 | $8K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 175 | $7K |
| 87070 | <1% | 653 | $7K | |
| 85610 | <1% | 1,241 | $7K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 168 | $6K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 716 | $6K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 15 | $6K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 64 | $5K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 956 | $4K |
| 81025 | <1% | 697 | $4K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 801 | $3K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 57 | $3K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 576 | $3K |
| G0378 | Hospital observation service, per hour | <1% | 249 | $2K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,026 | $2K |
| 87077 | <1% | 470 | $2K | |
| 11045 | <1% | 207 | $2K | |
| 81003 | <1% | 548 | $2K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 26 | $2K |
| A9270 | Non-covered item or service | <1% | 2,480 | $2K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 246 | $1K |
| 87186 | <1% | 262 | $1K | |
| 84484 | <1% | 1,685 | $844.55 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 277 | $827.59 |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 32 | $798.31 |
| 87040 | <1% | 212 | $775.23 | |
| 83690 | <1% | 651 | $759.83 | |
| 82397 | <1% | 258 | $746.88 | |
| 85730 | <1% | 796 | $623.63 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 64 | $478.44 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 24 | $320.48 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 86 | $248.95 |
| 71046 | Radiologic examination, chest; 2 views | <1% | 33 | $154.12 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 595 | $137.41 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 36 | $115.64 |
| 36415 | Collection of venous blood by venipuncture | <1% | 111 | $54.28 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 417 | $48.74 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 187 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 135 | $0.00 |
| 83605 | 0% | 85 | $0.00 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 18 | $0.00 |
| J3490 | Unclassified drugs | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCARUSO, MARIA (CFO)
| Provider | Location | Paid |
|---|---|---|
| Galen of Florida, INC. | St Petersburg, FL | $7.15M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.